Pathologies of the atrial septum include different interatrial communications varying from patent foramen
ovale (PFO) to actual defects. Atrial septal defects (ASDs) may be localized within the fossa ovalis such as
the secundum type ASD or outside the region of fossa ovalis, such as the ostium primum defect and sinus venosus
defect. Over the last decades, the percutaneous closure of interatrial shunts has become a feasible and safe
method. During these procedures, the delicate balance between thrombotic risk, device sealing process and bleeding
risk is crucial. In this review, we sought to describe current available data on the antiplatelet and antithrombotic
management of patients after percutaneous ASD or PFO closure.
Keywords: Patent foramen ovale, atrial septal defect, occluder devices, structural heart disease, fossa ovalis, interatrial shunts.
Rights & PermissionsPrintExport